Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Progen Pharmaceuticals has reported positive preliminary efficacy results from a Phase II investigator-initiated trial of PI-88 in combination with the chemotherapeutic agent Taxotere or docetaxel administered to patients with prostate cancer.
Subscribe to our email newsletter
In this trial 70% of the 55 patients showed decrease in serum Prostate Specific Antigen (PSA) of greater than 50% for three weeks or longer. These efficacy results compare favourably with the pivotal TAX327 Taxotere registration trial, where 45% of patients had at least a 50% decrease in serum PSA level.